Literature DB >> 10890672

Plasma dehydroepiandrosterone levels during experimental endotoxemia and anti-inflammatory therapy in humans.

S R Bornstein1, G W Wolkersdörfer, R Tauchnitz, H L Preas, G P Chrousos, A F Suffredini.   

Abstract

OBJECTIVE: To measure the effect of experimental endotoxemia and anti-inflammatory therapy on plasma dehydroepiandrosterone (DHEA) levels in humans.
DESIGN: Controlled, randomized, single-blind, prospective clinical study.
SETTING: Monitored unit in research hospital.
SUBJECTS: Twelve healthy volunteers served as their own controls and were randomized to receive intravenous endotoxin (Escherichia coli) or saline separated by 1 wk. Six were randomized to receive ibuprofen, a cyclooxygenase inhibitor, and six were given placebo.
INTERVENTIONS: Measurement of vital signs and hormones during a 24-hr period.
MEASUREMENTS AND MAIN RESULTS: All subjects given endotoxin had a significant increase in plasma DHEA, cortisol, and adrenocorticotropic hormone (ACTH) levels (all p = .02). DHEA levels were maximum at 2 hrs and returned to baseline values by 6 hrs. Ibuprofen administration significantly blunted the endotoxin-induced increase in DHEA secretion (p = .001), whereas the increase in cortisol and ACTH was not affected.
CONCLUSIONS: Acute endotoxemia leads to a rise in plasma DHEA levels in humans. Maximum levels of DHEA but not cortisol or ACTH were blunted by ibuprofen, suggesting a different regulation of these synthetic pathways in the adrenal cortex inner zone during acute inflammation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10890672     DOI: 10.1097/00003246-200006000-00073

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  1 in total

1.  A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.

Authors:  Marit M Melssen; Gina R Petroni; Kimberly A Chianese-Bullock; Nolan A Wages; William W Grosh; Nikole Varhegyi; Mark E Smolkin; Kelly T Smith; Nadejda V Galeassi; Donna H Deacon; Elizabeth M Gaughan; Craig L Slingluff
Journal:  J Immunother Cancer       Date:  2019-06-27       Impact factor: 13.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.